Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / IGFBP1

IGFBP1

Basics

Aliases:
This biomarker is also known as:
  • AFBP,
  • IBP-1,
  • PP12,
  • IGF-BP25,
  • IBP1,
  • IGF-binding protein 1,
  • insulin-like growth factor binding protein 1,
  • Placental protein 12,
  • hIGFBP-1,
  • IGFBP-1,
  • alpha-pregnancy-associated endometrial globulin,

View in BioMuta

Description…

IGFBP1, a secreted protein, is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. It binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. IGFBP1 promotes cell migration.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: IGFBP1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Curated

Overview

IGFBP1 has not been shown to be a strong biomarker for ovarian cancer.

Performance Comment

Of the ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. IGFBP1 alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.